NTLA Earnings & Financial Statements
Intellia Therapeutics, Inc.
$11.43
-$0.48(-4.03%)
51
Overall
60
Value
54
Tech
39
Quality
Market Cap
$1.60B
Volume
5.44M
52W Range
$7.95 - $28.25
Target Price
$22.33
NTLA earnings and financial statements: Intellia Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
NTLA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $67.67M | $57.88M | $36.27M | $52.12M | $33.05M |
| Operating income | -$440.99M | -$534.26M | -$515.29M | -$458.16M | -$267.85M |
| EBITDA | -$396.77M | -$508.74M | -$472.22M | -$466.61M | -$253.40M |
| Net income | -$412.69M | -$519.02M | -$481.19M | -$474.19M | -$267.89M |
| EPS (diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $842.13M | $1.19B | $1.30B | $1.52B | $1.29B |
| Total liabilities | $170.73M | $319.06M | $250.81M | $284.53M | $254.22M |
| Shareholders’ equity | $671.39M | $871.96M | $1.05B | $1.24B | $1.04B |
| Cash and equivalents | $155.46M | $189.18M | $226.75M | $523.51M | $123.41M |
| Long-term debt | $66.85M | $189.95M | $96.75M | $114.02M | $64.91M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$394.74M | -$348.88M | -$394.09M | -$333.29M | -$225.03M |
| Capital expenditure | -$1.13M | -$5.78M | -$13.98M | -$58.39M | -$12.76M |
| Free cash flow | -$395.87M | -$354.66M | -$408.07M | -$391.68M | -$237.79M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NTLA | $11.43 | -4.0% | 5.44M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Intellia Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW